Castle Biosciences Reports Second Quarter 2023 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Tech selloff weighs down Wall Street as bond yields climb
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Francisco Partners to acquire Weave Communications for $650M
Castle Biosciences Inc. (CSTL) Tops Q2 EPS by 22c; Offers FY23 Revenue Guidance
August 2, 2023 4:25 PM EDTCastle Biosciences Inc. (NASDAQ: CSTL) reported Q2 EPS of ($0.70), $0.22 better than the analyst estimate of ($0.92). Revenue for the quarter came in at $50.14 million versus the consensus estimate of $44.24 million.
GUIDANCE:
Castle Biosciences Inc. sees FY2023 revenue of $180 million, versus the... More
